Treatment in Germany - see top hospital ratings and lists of best specialists, up-to-date information prices adresses and contacts
15.11.2018 15:34:57
Glaucoma is one of the most dangerous eye diseases and the second most common cause of blindness in the world. Much of this condition, in which cells in the optic nerve and retina die off, is still unknown and the subject of clinical and experimental research. From the "Experimental Eye Research Institute" of the Eye Clinic at the University Hospital Bochum comes a study on the possible triggers of this condition, which has now been rated by the "European Vision Research Institute" as one of the five best publications of the last year.
Every year, the European Vision Research Institute identifies five scientific papers of special importance for the study of vision and diseases that threaten the most important sensory perception of man. In addition to studies from Switzerland, France and Sweden, the recently published list of the "Top Five" of this branch of science also includes the work of the research group headed by Dr. Sabrina Reinehr. The scientist and her team had demonstrated important insights into the mechanisms of glaucoma in the laboratory. The Bochum researchers examined the role of the complement system in animal models and found evidence that in glaucoma in addition to the known risk factor, the increased intraocular pressure, also autoimmune reactions play an important role. "The findings on cell death in glaucoma," says Dr. Reinehr "may help to develop new therapies and detect glaucoma disease earlier, before neurobiognomy, which damages neurons, is common in Green Star."
The appreciation of the Bochum study by the "European Vision Research Institute" underlines the role of research at the Eye Clinic. The focus of research at Bochum's "Experimental Eye Research Institute" is on neurodegenerative diseases such as glaucoma and age-related macular degeneration (AMD), but also on neurological conditions with potential eye involvement such as multiple sclerosis (MS). "Research on these conditions, with so many questions left open," says Ophthalmology Director Professor Burkhard Dick, "is a very important area for us at the clinic, whether we are ophthalmologists or scientists. Today we have an internationally respected high standard of care in the field of glaucoma and cataract surgery and the surgical treatment of defective vision, but as doctors we must not be satisfied unless we can effectively help people with such neurodegenerative diseases."
